Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04197687
Title TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Mayo Clinic

breast adenocarcinoma


Ado-trastuzumab emtansine + Sargramostim + TPIV100

Ado-trastuzumab emtansine + Sargramostim

Pertuzumab + Trastuzumab

Ado-trastuzumab emtansine

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.